Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

Grail stock hit a 12-month high after receiving a positive recommendation from an FDA panel for its Galleri cancer screening test.

FDA approval and insurer adoption of Galleri are expected to boost the company's growth.

However, the price that insurers are willing to pay for the test is a critical risk factor for investors.

Grail's stock price reflects the potential of the test, but investors should be aware of the pricing risk.